AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22843637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based walking programme with two 30-minute physical activity consultations from a trained practice nurse
Number of subjects: 284
Study 22843637 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal care for 12 weeks)
Number of subjects: 284
Study 22843637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based walking programme
Number of subjects: 284
Study 20716081 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam with fentanyl
Number of subjects: 120
Study 20716081 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl
Number of subjects: 120
Study 20716081 — intervention group
Group type: COMPARATOR
Intervention: Ketamine with fentanyl
Number of subjects: 120
Study 17379489 — intervention group
Group type: EXPERIMENTAL
Intervention: Closeness to death
Number of subjects: 107
Study 17379489 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status and baseline QoL
Number of subjects: 107
Study 15665012 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 10 mg QD or higher
Number of subjects: 60
Study 15665012 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Number of subjects: 60
Study 15665012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12164298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick assay for detection of Salmonella typhi-specific IgM antibodies
Number of subjects: 0
Study 12164298 — intervention group
Group type: COMPARATOR
Intervention: Culture testing
Number of subjects: 0
Study 12164298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick assay for culture-negative patients
Number of subjects: 0
Study 10564562 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin gel-100 microg/g
Number of subjects: 922
Study 10564562 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 922
Study 8728346 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 1 mg once daily for 10 days, followed by 2 mg once daily for 5 days (morning administration)
Number of subjects: 24
Study 8728346 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 1 mg once daily for 10 days, followed by 2 mg once daily for 5 days (evening administration)
Number of subjects: 24
Study 8728346 — intervention group
Group type: COMPARATOR
Intervention: Comparison of morning and evening administration of doxazosin
Number of subjects: 24
Study 1996576 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD, 0.6 mg/kg/d)
Number of subjects: 9
Study 1996576 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (NPD, 1.3 mg/kg/d)
Number of subjects: 9
Study 6481662 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week aerobic exercise program
Number of subjects: 105
Study 6481662 — intervention group
Group type: COMPARATOR
Intervention: Meditation program
Number of subjects: 105
Study 6481662 — intervention group
Group type: COMPARATOR
Intervention: Music appreciation program
Number of subjects: 105
Study 6481662 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained subjects in Experiment 1
Number of subjects: 105
Study 6481662 — intervention group
Group type: COMPARATOR
Intervention: Untrained subjects in Experiment 1
Number of subjects: 105
Study 6481662 — intervention group
Group type: COMPARATOR
Intervention: Training subjects in Experiment 1
Number of subjects: 105
Study 30664303 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (300 mg/day, titrated over 6 weeks and maintained for 6 weeks)
Number of subjects: 0
Study 30664303 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 30106614 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aid (flowchart)
Number of subjects: 138
Study 30106614 — intervention group
Group type: COMPARATOR
Intervention: No visual aid
Number of subjects: 138
Study 29298017 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 63
Study 29298017 — intervention group
Group type: EXPERIMENTAL
Intervention: Local collagen treatment
Number of subjects: 63
Study 29298017 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 63
Study 24751581 — intervention group
Group type: EXPERIMENTAL
Intervention: 190‐NBI
Number of subjects: 360
Study 24751581 — intervention group
Group type: COMPARATOR
Intervention: HD‐WL
Number of subjects: 360
Study 22017810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 69
Study 22017810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 69
Study 20668152 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based glucose monitoring system (IBGMS)
Number of subjects: 50
Study 20668152 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 50
Study 18317742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate injection (0.1 ml, 0.5 M) into latent MTrPs
Number of subjects: 14
Study 18317742 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection (0.1 ml, 0.9%) into latent MTrPs
Number of subjects: 14
Study 18317742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate injection into non-MTrPs
Number of subjects: 14
Study 18317742 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection into non-MTrPs
Number of subjects: 14
Study 18317742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate injection compared to isotonic saline
Number of subjects: 14
Study 15772059 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (6-month progressive program)
Number of subjects: 51
Study 15772059 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-intensity yoga and deep breathing)
Number of subjects: 51
Study 12466347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 363
Study 12466347 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 363
Study 12466347 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGFBP‐1
Number of subjects: 363
Study 10202876 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (oral E2, 1 mg daily for 12 months, then 2 mg daily) with 5 or 10 mg of dydrogesterone
Number of subjects: 27
Study 10202876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study 7607192 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (N; 1.2 mmol.l‐1; 3 ml)
Number of subjects: 9
Study 7607192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P; 0.9% saline; 3 ml)
Number of subjects: 9
Study 1975891 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 lux artificial full‐spectrum light
Number of subjects: 23
Study 1975891 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 lux artificial full‐spectrum light
Number of subjects: 23
Study 1975891 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (not exposed to SAD conditions)
Number of subjects: 23
Study 393356 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg intravenous infusion over 30 minutes)
Number of subjects: 12
Study 393356 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg orally thrice daily for six days)
Number of subjects: 12
Study 31843374 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone stocked in pharmacies
Number of subjects: 524
Study 31843374 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone availability on the day of contact
Number of subjects: 524
Study 31843374 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription requirement for naloxone
Number of subjects: 524
Study 31843374 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification requirement for naloxone
Number of subjects: 524
Study 31843374 — intervention group
Group type: EXPERIMENTAL
Intervention: Average price of naloxone nasal spray
Number of subjects: 524
Study 30612327 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP adapted to achieve the best dynamic lung compliance
Number of subjects: 100
Study 30612327 — intervention group
Group type: COMPARATOR
Intervention: PEEP of 10 cm H2O (control group)
Number of subjects: 100
Study 28328179 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily
Number of subjects: 1540
Study 28328179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1540
Study 26010304 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched health messages for non-intenders
Number of subjects: 205
Study 26010304 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatched health messages for non-intenders
Number of subjects: 205
Study 26010304 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched health messages for intenders
Number of subjects: 205
Study 26010304 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 205
Study 23817865 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program (exercise, diet, hot bath)
Number of subjects: 61
Study 23817865 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet intervention
Number of subjects: 61
Study 23817865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot bath intervention
Number of subjects: 61
Study 23817865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 22092168 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion
Number of subjects: 50
Study 22092168 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 50
Study 18825612 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet type I (low fat)
Number of subjects: 131
Study 18825612 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet type II (low carbohydrate)
Number of subjects: 131
Study 18825612 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets for carriers of T variant
Number of subjects: 131
Study 16943177 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 27
Study 16943177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12905078 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest autograft
Number of subjects: 36
Study 12905078 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular titanium cages
Number of subjects: 36
Study 11587994 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke (ETS) exposure
Number of subjects: 37
Study 11587994 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoke inhalation
Number of subjects: 37
Study 11587994 — intervention group
Group type: COMPARATOR
Intervention: Sham inhalation
Number of subjects: 37
Study 9403257 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine rinsing 4 times daily
Number of subjects: 40
Study 9403257 — intervention group
Group type: COMPARATOR
Intervention: Sterile water rinsing (Control)
Number of subjects: 40
Study 7520905 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone at doses of 6, 10, and 16 mg/day
Number of subjects: 0
Study 7520905 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol at a dose of 20 mg/day
Number of subjects: 0
Study 7520905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3294067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg/day)
Number of subjects: 8
Study 3294067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 5687606 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically observed foetal heart rate > 160 beats per minute
Number of subjects: 0
Study 5687606 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady foetal heart rate 100-120 beats per minute
Number of subjects: 0
Study 31234672 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient visits for migraine in the physician's office
Number of subjects: 168
Study 31234672 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency room visits
Number of subjects: 168
Study 31234672 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for migraine
Number of subjects: 168
Study 31234672 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood tests
Number of subjects: 168
Study 31234672 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 168
Study 31234672 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Number of subjects: 168
Study 31234672 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tomography (CT) scan
Number of subjects: 168
Study 28134562 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 44
Study 28134562 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 28977202 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 15
Number of subjects: 30
Study 28977202 — intervention group
Group type: COMPARATOR
Intervention: PEEP 10
Number of subjects: 30
Study 28977202 — intervention group
Group type: COMPARATOR
Intervention: PEEP 12
Number of subjects: 30
Study 23714166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterimar™
Number of subjects: 31
Study 23714166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus Rinse™
Number of subjects: 31
Study 21848706 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast, 500 µg once daily
Number of subjects: 410
Study 21848706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 20141008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg)
Number of subjects: 100
Study 20141008 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxypin (150 mg)
Number of subjects: 100
Study 20141008 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 100
Study 17270317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (7.2 g/day for 14 days)
Number of subjects: 8
Study 17270317 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 8
Study 17270317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (7.2 g/day for 14 days) in fasting conditions
Number of subjects: 8
Study 15073101 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 187
Study 15073101 — intervention group
Group type: COMPARATOR
Intervention: IFN + 1-beta-D-arabinofuranosylcytosine
Number of subjects: 187
Study 11231986 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine [64 nmol.day(‐)(1) (0.05 mg.day(‐)(1))]
Number of subjects: 12
Study 11231986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11231986 — intervention group
Group type: COMPARATOR
Intervention: Both groups (L-thyroxine and placebo)
Number of subjects: 12
Study 9022429 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine follow up restricted to the time of mammography
Number of subjects: 211
Study 9022429 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule of clinic visits
Number of subjects: 211
Study 7930987 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation in patients with overt accessory AV connections (group 1)
Number of subjects: 51
Study 7930987 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation in patients with concealed accessory AV connections (group 2)
Number of subjects: 51
Study 3369246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program for rheumatoid arthritis (8 hours over 3 months)
Number of subjects: 34
Study 29544801 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal-mineral-content diet (group D)
Number of subjects: 98
Study 29544801 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (group S)
Number of subjects: 98
Study 29544801 — intervention group
Group type: COMPARATOR
Intervention: No changes in diet or zinc supplementation (group C)
Number of subjects: 98
Study 26985696 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU Device 1
Number of subjects: 20
Study 26985696 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU Device 2
Number of subjects: 20
Study 23868932 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month follow-up interval
Number of subjects: 155
Study 23868932 — intervention group
Group type: COMPARATOR
Intervention: 3-month follow-up interval
Number of subjects: 155
Study 23520976 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg/mL, 0.5 mL)
Number of subjects: 28
Study 23520976 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline, 9 mg/mL, 0.5 mL)
Number of subjects: 28
Study 20535948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (antiangiogenesis therapy)
Number of subjects: 0
Study 20535948 — intervention group
Group type: COMPARATOR
Intervention: Small molecules of VEGF-TKI
Number of subjects: 0
Study 18177773 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy
Number of subjects: 6000
Study 18177773 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 6000
Study 16504154 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNalfa‐2b 20 MU/m2/d IV 5 days/week x 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25 to 28 (DD/DI arm)
Number of subjects: 169
Study 16504154 — intervention group
Group type: COMPARATOR
Intervention: IFNalfa‐2b 20 MU/m2/d IV 5 days/week x 4 weeks followed by 10 MU/m2 SC three times per week x 48 weeks (HDI arm)
Number of subjects: 169
Study 16504154 — intervention group
Group type: EXPERIMENTAL
Intervention: DD/DI arm
Number of subjects: 169
Study 14621092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal breathing
Number of subjects: 12
Study 14621092 — intervention group
Group type: COMPARATOR
Intervention: Oral breathing
Number of subjects: 12
Study 10732258 — intervention group
Group type: EXPERIMENTAL
Intervention: CASA volunteers
Number of subjects: 200
Study 10732258 — intervention group
Group type: COMPARATOR
Intervention: No CASA volunteers (Control)
Number of subjects: 200
Study 8881615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprotte spinal needle orientation pointing cephalad (group A)
Number of subjects: 100
Study 8881615 — intervention group
Group type: COMPARATOR
Intervention: Sprotte spinal needle orientation pointing right lateral (group B)
Number of subjects: 100
Study 8881615 — intervention group
Group type: COMPARATOR
Intervention: Sprotte spinal needle orientation pointing left lateral (group C)
Number of subjects: 100
Study 8881615 — intervention group
Group type: COMPARATOR
Intervention: Sprotte spinal needle orientation pointing caudad (group D)
Number of subjects: 100
Study 8267489 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-factor Xa monitoring (targeted range, 0.35 to 0.67 U/mL)
Number of subjects: 131
Study 8267489 — intervention group
Group type: COMPARATOR
Intervention: APTT monitoring (targeted range, 60 to 85 seconds)
Number of subjects: 131
Study 8267489 — intervention group
Group type: COMPARATOR
Intervention: APTT monitoring
Number of subjects: 131
Study 8267489 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-factor Xa monitoring
Number of subjects: 131
Study 3114564 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.06‐2 micrograms in 0.1 ml saline)
Number of subjects: 21
Study 3114564 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (20, 40, 60, and 120 mg, p.o.)
Number of subjects: 21
Study 3114564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29336898 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 51
Study 29336898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 51
Study 29336898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 27039756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth Exercising Device (MED) in subgroup A1 (n=53)
Number of subjects: 231
Study 27039756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth Exercising Device (MED) in subgroup A2 (n=46)
Number of subjects: 231
Study 27039756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth Exercising Device (MED) in subgroup A3 (n=18)
Number of subjects: 231
Study 27039756 — intervention group
Group type: COMPARATOR
Intervention: Control group B1 (n=50)
Number of subjects: 231
Study 27039756 — intervention group
Group type: COMPARATOR
Intervention: Control group B2 (n=48)
Number of subjects: 231
Study 27039756 — intervention group
Group type: COMPARATOR
Intervention: Control group B3 (n=16)
Number of subjects: 231
Study 24245838 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 285
Study 24245838 — intervention group
Group type: COMPARATOR
Intervention: Internet (control group)
Number of subjects: 285
Study 24245838 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruptiveness
Number of subjects: 285
Study 23726115 — intervention group
Group type: EXPERIMENTAL
Intervention: voluntary deep-inspiratory breath-hold (v_DIBH)
Number of subjects: 23
Study 23726115 — intervention group
Group type: COMPARATOR
Intervention: deep-inspiratory breath-hold with the active breathing coordinator™ (ABC_DIBH)
Number of subjects: 23
Study 20627451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity behavioral treatment (average 6.5h per week)
Number of subjects: 34
Study 20627451 — intervention group
Group type: COMPARATOR
Intervention: Regular intervention (control group)
Number of subjects: 34
Study 18979977 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image challenge with thin model images and smoking cues
Number of subjects: 62
Study 18979977 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image challenge with thin model images without smoking cues
Number of subjects: 62
Study 18979977 — intervention group
Group type: COMPARATOR
Intervention: Control images
Number of subjects: 62
Study 16409338 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT service (Inpatient Management of acute Pain and Advice on Clinical Treatment)
Number of subjects: 590
Study 16409338 — intervention group
Group type: COMPARATOR
Intervention: Standard acute pain management (baseline phase)
Number of subjects: 590
Study 14636098 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervals (MAX)
Number of subjects: 16